Penn Medicine
Help | Search | Site Map | Contact   
faculty photo

Gerald P Linette, MD, PhD

Professor of Medicine at the Hospital of the University of Pennsylvania
Attending , Hospital of the University of Pennsylvania
Chief Medical Officer for Cancer Immunotherapy, Center for Cellular Immunotherapy, University of Pennsylvania
Clinical Director , Parker Institute, University of Pennsylvania
Member, Immunology Graduate Group, University of Pennsylvania
Department: Medicine

Contact information
University of Pennsylvania
Center for Cellular Immunotherapies
3400 Civic Center Blvd
SPE 8-102
Philadelphia, PA 19104
Office: 215-573-7032
Graduate Group Affiliations
Education:
BS (Biology)
St. Joseph's University , 1980.
MD
Georgetown University School of Medicine, 1990.
PhD (Microbiology )
Georgetown University School of Medicine , 1990.
Post-Graduate Training
Intern in Internal Medicine , Barnes Hospital, 1990-1991.
Resident in Internal Medicine, Barnes Hospital , 1991-1992.
Research Fellow in Molecular Oncology, Washington University , 1992-1995.
Fellow in Hematology-Oncology, Massachusetts General Hospital, 1995-1998.
Certifications
American Board of Internal Medicine - Internal Medicine , 1997.
American Board of Internal Medicine - Medical Oncology , 2010.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Description of Clinical Expertise

1. Medical Oncology
2. Melanoma and other advanced skin cancers
3. Neuro-Oncology

Description of Research Expertise

Human Cancer Immunology is the focus of our laboratory and clinical efforts.

The development of a systematic approach to identify and validate cancer neoantigens is a primary interest of our research laboratory. In collaboration with experts in cancer genomics, we have created a bioinformatics pipeline to identify tumor-specific missense mutations which encode neoantigenic peptides. Our team has successfully applied this strategy to develop the first test of personalized cancer vaccination in humans with melanoma. Ongoing proof-of-concept trials aim to test neoantigens as targets for various immunotherapy strategies in melanoma and other solid tumors. In particular, our work aims to characterize the functional and phenotypic landscape of vaccine-elicited T cells using molecular technologies.

A related interest is the development of cellular therapies for cancer. We are currently exploring the development of neoantigen-specific T cell therapy for use in patients. We work collaboratively with research groups in order to find novel solutions to overcome the inherent obstacles created by the tumor microenvironment. The long term goal is to advance and test personalized medicine based approaches in cancer patients. For more information, please see the Center for Cellular Immunotherapies home page.

Selected Publications

Linette GP, Carreno BM.: Neoantigen Vaccines Pass the Immunogenicity Test. Trends Mol Med. August 2017.

Larkin J, Minor D, D'Angelo S, Neyns B, Smylie M, Miller WH Jr, Gutzmer R, Linette G, Chmielowski B, Lao CD, Lorigan P, Grossmann K, Hassel JC, Sznol M, Daud A, Sosman J, Khushalani N, Schadendorf D, Hoeller C, Walker D, Kong G, Horak C, Weber J.: Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial. J Clin Oncol. July 2017.

Zenga J, Nussenbaum B, Cornelius LA, Linette GP, Desai SC.: Management Controversies in Head and Neck Melanoma: A Systematic Review. JAMA Facial Plast Surg 19(1): 53-62, Jan 1 2017.

Hodi FS1, Chesney J, Pavlick AC, Robert C, Grossmann KF, McDermott DF, Linette GP, Meyer N, Giguere JK, Agarwala SS, Shaheen M, Ernstoff MS, Minor DR, Salama AK, Taylor MH, Ott PA, Horak C, Gagnier P, Jiang J, Wolchok JD, Postow MA.: Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol 17(11): 1558-1568, Nov 2016.

Kaufman HL, Russell J, Hamid O, Bhatia S, Terheyden P, D'Angelo SP, Shih KC, Lebbé C, Linette GP, Milella M, Brownell I, Lewis KD, Lorch JH, Chin K, Mahnke L, von Heydebreck A, Cuillerot JM, Nghiem P.: Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol 17(10): 1374-1385, Oct 2016.

Hundal J, Carreno BM, Petti AA, Linette GP, Griffith OL, Mardis ER, Griffith M: pVAC-Seq: A genome-guided in silico approach to identifying tumor neoantigens. Genome Med 8(1): 11-19, Jan 29 2016.

Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, Linette GP, Meyer N, Giguere JK, Agarwala SS, Shaheen M, Ernstoff MS, Minor D, Salama AK, Taylor M, Ott PA, Rollin LM, Horak C, Gagnier P, Wolchok JD, Hodi FS.: Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 372(21): 2006-17, May 21 2015.

Carreno BM, Magrini V, Becker-Hapak M, Kaabinejadian S, Hundal J, Petti AA, Ly A, Lie WR, Hildebrand WH, Mardis ER, Linette GP.: A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science 348(6236): 803-8, May 15 2015.

Ding L, Kim M, Dees ND, Kanchi KL, Lu C, Griffith M, Fenstermacher D, Sung H, Miller CA, Goetz B, Wendl MC, Griffith O, Cornelius LA, Linette GP, Sondak VK, Fields RC, Ley TJ, Mulé JJ, Wilson RK, Weber JS.: Clonal Architecture and Driver Mutations in Metastatic Melanoma. PLOS One. 9(11): 9e111153, Nov 13 2014.

Carreno BM, Becker-Hapak M, Huang A, Chan M, Alyasiry A, Lie WR, Aft RL, Cornelius LA, Trinkaus KM, Linette GP.: IL-12p70 producing patient DC vaccine elicits Tc1-polarized immunity. Journal of Clinical Investigation 123(8): 3383-94, Aug 2013.

back to top
Last updated: 09/24/2017
The Trustees of the University of Pennsylvania
 
© The Trustees of the University of Pennsylvania. Site best viewed with Mozilla, NN, IE, or Safari.
SOM Home International Programs Penn Alumni Clinical Trials Centers and Institutes Departments Faculty Research Education Administration